Stock Analiz

Connect Biopharma Holdings Ltd CNTB

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$0.68Market cap $43M
Open the interactive analysis →

Connect Biopharma Holdings Ltd (CNTB) is a healthcare company listed in the US with a market value of about $43M. In the twelve months to June 30, 2026 it had revenue of $3M and net income of -$69M, a net margin of -2336.3%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -54%.

About Connect Biopharma Holdings

Connect Biopharma Holdings is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 5 years in our data. It spends 59059% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S14.4
P/B1.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-142.2%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-99.8%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-43373.8%
ROIC (5-yr avg.)-53.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 5 years

Fiscal yearTTM20252024202320222021
Revenue$3M$64000$26M$0——
Net income-$69M-$55M-$16M-$62M-$118M-$202M
Free cash flow-$61M-$52M-$24M-$48M-$106M-$88M
EPS (diluted)$-1.19$-0.88$-0.25$-0.99$-1.88$-3.21
Net margin-2336.3%-86687.5%-60.0%———
ROIC—-107.5%-19.2%-53.5%-59.5%-28.5%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Connect Biopharma Holdings pay a dividend?

Not currently.

Is Connect Biopharma Holdings a good stock to buy?

We do not give buy or sell advice. Connect Biopharma Holdings scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.